Literature DB >> 7419680

Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study.

D Bression, A M Brandi, M P Martres, A Nousbaum, F Cesselin, J Racadot, F Peillon.   

Abstract

Dopaminergic receptors were observed on the membranes of 26 human PRL-secreting adenomas. Two binding sites were found for [3H]domperidone, a selective dopamine antagonist, with a Kd1 of 0.29 +/- 0.06 nM and a Kd2 of 4.19 +/- 0.7 nM (n = 5). Bmax1 and Bmax2 (maximum numbers of binding sites, first and second sites, respectively) varied from one adenoma to another. When considering Bmax1, two different categories of PRL-secreting adenomas were distinguished, one with a concentration of receptor over 250 fmol/mg protein and others with lower concentrations of receptor (< 250 fmol/mg protein). In the latter, when considering the volume of the tumor, a higher plasma PRL level was found. Two binding sites for [3H]domperidone also were found in the normal human hypophysis with Kd values similar to those of the adenomas (0.18 +/- 0.04 and 3.95 +/- 0.35 nM). The same number of binding sites was observed in normal pituitaries and in PRL-secreting adenomas. However, when considering the density of PRL-secreting cells in the two different tissues (prolactinomas contain 2 or 3 times more PRL-secreting cells than human pituitary tissue), one may suspect a defect in the dopaminergic inhibiting control in PRL-secreting adenomas.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7419680     DOI: 10.1210/jcem-51-5-1037

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Perifusion system: its use in the study of the neuroendocrine control of human pituitary tumoral cells.

Authors:  D Joubert; A M Brandi; F Peillon
Journal:  Cell Biol Toxicol       Date:  1992 Jul-Sep       Impact factor: 6.691

Review 2.  Hyperprolactinemia: neuroendocrine and diagnostic aspects.

Authors:  F Camanni; E Ciccarelli; E Ghigo; E E Müller
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

3.  Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.

Authors:  K Kovacs; L Stefaneanu; E Horvath; R V Lloyd; I Lancranjan; M Buchfelder; R Fahlbusch
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 4.  Positron emission tomography applied in the study of pituitary adenomas.

Authors:  C Muhr; M Bergström
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

5.  Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland.

Authors:  Rosario Pivonello; Marlijn Waaijers; Johan M Kros; Claudia Pivonello; Cristina de Angelis; Alessia Cozzolino; Annamaria Colao; Steven W J Lamberts; Leo J Hofland
Journal:  Endocrine       Date:  2016-10-13       Impact factor: 3.633

6.  Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.

Authors:  M Muratori; M Arosio; G Gambino; C Romano; O Biella; G Faglia
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.